Hydrocortisone Pharmis (Hydrocortisone Sodium Succinate)

Hydrocortisone Pharmis is indicated for conditions that require immediate glucocorticoid replacement or potent anti‑inflammatory action. It is employed in clinical situations where rapid systemic effects are essential, such as adrenal insufficiency and severe inflammatory states.

• Management of adrenal insufficiency and adrenal crisis.
• Treatment of hypotension secondary to shock when glucocorticoid support is needed.
• Control of severe inflammatory conditions unresponsive to oral therapy.
• Adjunct therapy in severe allergic reactions requiring systemic steroids.
• Short‑term immunosuppression in transplant or autoimmune protocols under specialist supervision.

• Hydrocortisone sodium succinate is a pro‑drug that is rapidly converted to active hydrocortisone after intravenous or intramuscular injection. The active molecule penetrates cell membranes and binds cytoplasmic glucocorticoid receptors, forming a receptor‑ligand complex that translocates to the nucleus. This complex interacts with glucocorticoid response elements on DNA, altering transcription of multiple genes, which suppresses pro‑inflammatory cytokine production, stabilizes lysosomal membranes, and reduces leukocyte migration, producing anti‑inflammatory and immunosuppressive effects.

Like all systemic glucocorticoids, Hydrocortisone Pharmis may be associated with adverse reactions that vary in frequency and severity, typically observed during short‑term use or high‑dose therapy.

Common

• Transient increase in blood glucose levels.
• Mild electrolyte disturbances such as sodium retention.
• Headache or dizziness.
• Local irritation at the injection site.
• Gastrointestinal discomfort or nausea.
• Insomnia or mood alterations.
• Mild weight gain from fluid retention.

Serious

• Severe hypertension or fluid overload.
• Acute adrenal suppression after abrupt discontinuation.
• Allergic reactions including rash, bronchospasm, or anaphylaxis.
• Increased susceptibility to bacterial, viral, or fungal infections.
• Osteonecrosis or avascular necrosis with prolonged high‑dose therapy.

When prescribing Hydrocortisone Pharmis, clinicians should evaluate patient‑specific factors and monitor for conditions that could be worsened by systemic glucocorticoid exposure.

• Assess for uncontrolled diabetes or hyperglycemia before initiating therapy.
• Use caution in patients with hypertension, heart failure, or renal impairment.
• Screen for active infections; glucocorticoids may exacerbate bacterial, viral, or fungal diseases.
• Evaluate bone health, especially in long‑term or high‑dose regimens.
• Consider tapering strategies to avoid adrenal insufficiency after abrupt cessation.
• Monitor electrolyte balance, particularly sodium and potassium levels.

Hydrocortisone Pharmis can alter the pharmacokinetics or pharmacodynamics of several concomitant medicines; awareness of key interactions helps prevent adverse outcomes.

Avoid

• Concurrent use with potent CYP3A4 inducers (e.g., rifampin, phenytoin) that may reduce glucocorticoid efficacy.
• Simultaneous administration of systemic anticoagulants without dose adjustment, as glucocorticoids can enhance bleeding risk.

Use with caution

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) may increase risk of gastrointestinal ulceration.
• Live vaccines should be avoided because immunosuppression can diminish vaccine efficacy.
• Diuretics (especially loop diuretics) may potentiate electrolyte disturbances.
• Antidiabetic agents may require dose modification due to glucocorticoid‑induced hyperglycemia.